Cargando…

Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)

BACKGROUND: Evidence suggests an association between SARS-CoV-2 infection and worse performance on cognitive tests, and a higher risk of Parkinson’s disease (PD) and dementia up to 6 and 12 months after infection, respectively. Longer follow-ups with comparison groups are needed to clarify the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Araújo, Natália, Silva, Isa, Campos, Patrícia, Correia, Rita, Calejo, Margarida, Freitas, Pedro, Seco, Mariana, Ribeiro, Luís, Costa, Ana Rute, Morais, Samantha, Pereira, Susana, Firmino-Machado, João, Rodrigues, Rita, Pais, Joana, Ruano, Luís, Lunet, Nuno, Tedim-Cruz, Vítor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387627/
https://www.ncbi.nlm.nih.gov/pubmed/37518072
http://dx.doi.org/10.1136/bmjopen-2023-072981
_version_ 1785081925175607296
author Araújo, Natália
Silva, Isa
Campos, Patrícia
Correia, Rita
Calejo, Margarida
Freitas, Pedro
Seco, Mariana
Ribeiro, Luís
Costa, Ana Rute
Morais, Samantha
Pereira, Susana
Firmino-Machado, João
Rodrigues, Rita
Pais, Joana
Ruano, Luís
Lunet, Nuno
Tedim-Cruz, Vítor
author_facet Araújo, Natália
Silva, Isa
Campos, Patrícia
Correia, Rita
Calejo, Margarida
Freitas, Pedro
Seco, Mariana
Ribeiro, Luís
Costa, Ana Rute
Morais, Samantha
Pereira, Susana
Firmino-Machado, João
Rodrigues, Rita
Pais, Joana
Ruano, Luís
Lunet, Nuno
Tedim-Cruz, Vítor
author_sort Araújo, Natália
collection PubMed
description BACKGROUND: Evidence suggests an association between SARS-CoV-2 infection and worse performance on cognitive tests, and a higher risk of Parkinson’s disease (PD) and dementia up to 6 and 12 months after infection, respectively. Longer follow-ups with comparison groups are needed to clarify the potentially increased risk of neurodegenerative diseases in COVID-19 survivors, namely those infected before mass vaccination. METHODS: A prospective study started in July 2022 with four cohorts of 150 individuals each, defined according to SARS-CoV-2 infection and hospitalisation status between March 2020 and February 2021: cohort 1—hospitalised due to SARS-CoV-2 infection; cohort 2—hospitalised, COVID-19-free; cohort 3—infected, not hospitalised; cohort 4—not infected, not hospitalised. Cohort 2 will be matched to cohort 1 according to age, sex, level of hospitalisation care and length of stay; cohort 4 will be age-matched and sex-matched to cohort 3. Baseline, 1-year and 2-year follow-up evaluations will include: cognitive performance assessed with the Montreal Cognitive Assessment (MoCA) and neuropsychological tests; the assessment of prodromal markers of PD with Rapid Eye Movement Sleep Behaviour Disorder single-question Screen and self-reported olfactory and gustative alterations; screening of PD with the 9-item PD screening questionnaire; gait evaluation with Timed Up&Go test. Suspected cases of cognitive impairment and PD will undergo a clinical evaluation by a neurologist. Frequency measures of neurological complications, prodromal markers and diagnoses of dementia and PD, will be presented. The occurrence of cognitive decline—the difference between baseline and 1-year MoCA scores 1.5 SD below the mean of the distribution of the variation—will be compared between cohorts 1 and 2, and cohorts 3 and 4 with OR estimated using multivariate logistic regression. ETHICS AND DISSEMINATION: This study received ethics approval from the Ethics Committees of the health units Unidade Local de Saúde de Matosinhos and Centro Hospitalar de Entre Douro e Vouga, and informed consent is signed for participating. Results will be disseminated among the scientific community and the public.
format Online
Article
Text
id pubmed-10387627
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103876272023-08-01 Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19) Araújo, Natália Silva, Isa Campos, Patrícia Correia, Rita Calejo, Margarida Freitas, Pedro Seco, Mariana Ribeiro, Luís Costa, Ana Rute Morais, Samantha Pereira, Susana Firmino-Machado, João Rodrigues, Rita Pais, Joana Ruano, Luís Lunet, Nuno Tedim-Cruz, Vítor BMJ Open Epidemiology BACKGROUND: Evidence suggests an association between SARS-CoV-2 infection and worse performance on cognitive tests, and a higher risk of Parkinson’s disease (PD) and dementia up to 6 and 12 months after infection, respectively. Longer follow-ups with comparison groups are needed to clarify the potentially increased risk of neurodegenerative diseases in COVID-19 survivors, namely those infected before mass vaccination. METHODS: A prospective study started in July 2022 with four cohorts of 150 individuals each, defined according to SARS-CoV-2 infection and hospitalisation status between March 2020 and February 2021: cohort 1—hospitalised due to SARS-CoV-2 infection; cohort 2—hospitalised, COVID-19-free; cohort 3—infected, not hospitalised; cohort 4—not infected, not hospitalised. Cohort 2 will be matched to cohort 1 according to age, sex, level of hospitalisation care and length of stay; cohort 4 will be age-matched and sex-matched to cohort 3. Baseline, 1-year and 2-year follow-up evaluations will include: cognitive performance assessed with the Montreal Cognitive Assessment (MoCA) and neuropsychological tests; the assessment of prodromal markers of PD with Rapid Eye Movement Sleep Behaviour Disorder single-question Screen and self-reported olfactory and gustative alterations; screening of PD with the 9-item PD screening questionnaire; gait evaluation with Timed Up&Go test. Suspected cases of cognitive impairment and PD will undergo a clinical evaluation by a neurologist. Frequency measures of neurological complications, prodromal markers and diagnoses of dementia and PD, will be presented. The occurrence of cognitive decline—the difference between baseline and 1-year MoCA scores 1.5 SD below the mean of the distribution of the variation—will be compared between cohorts 1 and 2, and cohorts 3 and 4 with OR estimated using multivariate logistic regression. ETHICS AND DISSEMINATION: This study received ethics approval from the Ethics Committees of the health units Unidade Local de Saúde de Matosinhos and Centro Hospitalar de Entre Douro e Vouga, and informed consent is signed for participating. Results will be disseminated among the scientific community and the public. BMJ Publishing Group 2023-07-30 /pmc/articles/PMC10387627/ /pubmed/37518072 http://dx.doi.org/10.1136/bmjopen-2023-072981 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Araújo, Natália
Silva, Isa
Campos, Patrícia
Correia, Rita
Calejo, Margarida
Freitas, Pedro
Seco, Mariana
Ribeiro, Luís
Costa, Ana Rute
Morais, Samantha
Pereira, Susana
Firmino-Machado, João
Rodrigues, Rita
Pais, Joana
Ruano, Luís
Lunet, Nuno
Tedim-Cruz, Vítor
Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title_full Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title_fullStr Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title_full_unstemmed Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title_short Long-term neurological complications in COVID-19 survivors: study protocol of a prospective cohort study (NeurodegCoV-19)
title_sort long-term neurological complications in covid-19 survivors: study protocol of a prospective cohort study (neurodegcov-19)
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387627/
https://www.ncbi.nlm.nih.gov/pubmed/37518072
http://dx.doi.org/10.1136/bmjopen-2023-072981
work_keys_str_mv AT araujonatalia longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT silvaisa longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT campospatricia longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT correiarita longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT calejomargarida longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT freitaspedro longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT secomariana longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT ribeiroluis longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT costaanarute longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT moraissamantha longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT pereirasusana longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT firminomachadojoao longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT rodriguesrita longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT paisjoana longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT ruanoluis longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT lunetnuno longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19
AT tedimcruzvitor longtermneurologicalcomplicationsincovid19survivorsstudyprotocolofaprospectivecohortstudyneurodegcov19